ExpreS2ion Biotech Holding

Today, ExpreS2ion Biotechnologies’ management presented the results for the third quarter of 2025, provided further insights into the recent pipeline developments with focus on the malaria and breast cancer candidates, and shared the latest updates on partnerships agreements signed with SII.

ExpreS2ion Biotechnologies is expected to release its results for the first nine months of 2025 on 13 November 2025. Later the same day at 11:00 CET, the management team will present the financial results and key achievements in a live online presentation. The presentation will be followed by a Q&A session.

ExpreS2ion Biotech has entered a definitive licensing agreement with the Serum Institute of India (SII) for two blood-stage malaria vaccine candidates, RH5.1 and R78C, built on ExpreS2ion’s proprietary ExpreS2™ production platform. RH5.1 is currently in Phase II trials. An initial term sheet was announced with Serum Institute of India in November 2024, and today’s deal outlines that ExpreS2ion will receive upfront and milestone payments with an accumulated value of a low single-digit EUR amount, and in addition, is eligible for royalties ranging from below 1% to mid-single digits on future net sales.

Today, ExpreS2ion provided an update on the progress made during the third quarter across its malaria vaccine programs led by the University of Oxford.

transition from the discovery phase to preclinical development on the Nipah candidate